# US 2026/0091121 A2 · PSMA-STEAP1 DUAL VARIABLE DOMAIN IMMUNOGLOBULIN (DVD-Ig) MOLECULES AND DRUG CONJUGATES

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091121 A2
- Document ID: US20260091121A2
- Status: Published application
- Kind: A2
- Application number: 18/958,236
- Filed: 2024-11-25
- Published: 2026-04-02
- Earliest claimed: 2023-11-30
- Assignees: AbbVie Inc.
- Inventors: Edward Han; Andrew C. Phillips; Regina M. Reilly; Debra Touw; Zhihong Liu
- Web page: https://patentgrep.com/patent/US20260091121A2

## CPC

- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/68037: {the drug being a camptothecin [CPT] or derivatives}
- A61K 47/6869: {the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/31: multispecific
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/77: Internalization into the cell
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides dual variable domain immunoglobulin (DVD-Ig) molecules that bind to human STEAP1 and human PSMA and their drug conjugates, and methods of using the same.

## Claims

### Claim 1

A dual-variable domain immunoglobulin (DVD-Ig) drug conjugate comprising the following structure:
wherein n is 1 or 2,
wherein the DVD-Ig binds human STEAP1 and human PSMA,
wherein the DVD-Ig comprises two identical heavy chains and two identical light chains,
wherein each heavy chain comprises:
a) a first heavy chain variable domain (VH1) comprising VH1-CDR1 (SEQ ID NO: 3), VH1-CDR2 (SEQ ID NO: 4), and VH1-CDR3 (SEQ ID NO: 5);
b) a second heavy chain variable domain (VH2) comprising VH2-CDR1 (SEQ ID NO: 8), VH2-CDR2 (SEQ ID NO: 9), and VH2-CDR3 (SEQ ID NO: 10); and
c) an IgG1 heavy chain constant region (CH1CH2CH3);
wherein the VH1 and the VH2 are connected via a first peptide linker (L1), and each heavy chain is in the form of VH1-L1-VH2-CH1CH2CH3;
wherein each light chain comprises:
a) a first light chain variable domain (VL1) comprising VL1-CDR1 (SEQ ID NO: 13), VL1-CDR2 (SEQ ID NO: 14), and VL1-CDR3 (SEQ ID NO: 15);
b) a second light chain variable domain (VL2) comprising VL2-CDR1 (SEQ ID NO: 18), VL2-CDR2 (SEQ ID NO: 19), and VL2-CDR3 (SEQ ID NO: 20), and
c) a kappa light chain constant region (Cκ);
wherein the VL1 and the VL2 are connected via a second peptide linker (L2), and each light chain is in the form of VL1-L2-VL2-CK; and
wherein the first and the second heavy chains form a dimeric Fc region.

### Claim 2 (depends on 1)

The DVD-Ig drug conjugate of claim 1, wherein
the first heavy chain variable domain (VH1) comprises the amino acid sequence of SEQ ID NO: 2;
the second heavy chain variable domain (VH2) comprises the amino acid sequence of SEQ ID NO: 7;
the first light chain variable domain (VL1) comprises the amino acid sequence of SEQ ID NO: 12; and
the second light chain variable domain (VL2) comprises the amino acid sequence of SEQ ID NO: 17.

### Claim 3 (depends on 1)

The DVD-Ig drug conjugate of claim 1, wherein the first peptide linker (L1) comprises the amino acid sequence GGGGSGGGGS (SEQ ID NO: 6).

### Claim 4 (depends on 1)

The DVD-Ig drug conjugate of claim 1, wherein the second peptide linker (L2) comprises the amino acid sequence GGSGGGGSG (SEQ ID NO: 16).

### Claim 5 (depends on 1)

The DVD-Ig drug conjugate of claim 1, wherein the IgG1 heavy chain constant region (CH1CH2CH3) comprises the amino acid sequence of SEQ ID NO: 21 or 23.

### Claim 6 (depends on 1)

The DVD-Ig drug conjugate of claim 1, wherein the kappa light chain constant region (Cκ) comprises the amino acid sequence of SEQ ID NO: 22.

### Claim 7 (depends on 1)

The DVD-Ig drug conjugate of claim 1,
wherein each of the heavy chains comprise the amino acid sequence of SEQ ID NO: 1 or 24; and
wherein each light chain comprises the amino acid sequence of SEQ ID NO: 11.

### Claim 8 (depends on 1)

The DVD-Ig drug conjugate of claim 1, wherein the first heavy chain and the second heavy chain are connected by two disulfide bridges, and wherein the two disulfide bridges are between the cysteine in position 226 of the first heavy chain and the cysteine in position 226 of the second heavy chain, and between the cysteine in position 229 of the first heavy chain and the cysteine in position 229 of the second heavy chain according to EU numbering.

### Claim 9 (depends on 1)

The DVD-Ig drug conjugate of claim 1, wherein the Top1i linker-Drugs are conjugated to the cysteines at position C220 of the first and the second heavy chains of the DVD-Ig according to EU numbering.

### Claim 10 (depends on 1)

The DVD-Ig drug conjugate of claim 1, wherein n is 1.

### Claim 11 (depends on 1)

The DVD-Ig drug conjugate of claim 1, wherein n is 2.

### Claim 12

A dual-variable domain immunoglobulin (DVD-Ig) drug conjugate comprising the following structure:
wherein n is 2, and wherein the DVD-Ig binds human STEAP1 and human PSMA, and comprises two identical heavy chains and two identical light chains,
wherein each of the heavy chains comprise the amino acid sequence of SEQ ID NO: 1 or 24; and
wherein each light chain comprises the amino acid sequence of SEQ ID NO: 11;
wherein the first heavy chain and the second heavy chain are connected by two disulfide bridges, and wherein the two disulfide bridges are between the cysteine in position 226 of the first heavy chain and the cysteine in position 226 of the second heavy chain, and between the cysteine in position 229 of the first heavy chain and the cysteine in position 229 of the second heavy chain according to EU numbering; and
wherein the Top1i linker-Drugs are conjugated to the cysteines at position C220 of the first and the second heavy chains of the DVD-Ig according to EU numbering.

### Claim 13

A dual-variable domain immunoglobulin (DVD-Ig) drug conjugate comprising the following structure:
wherein n is 2, and wherein the DVD-Ig binds human STEAP1 and human PSMA, and comprises two identical heavy chains and two identical light chains.

### Claim 14

A pharmaceutical composition comprising a dual-variable domain immunoglobulin (DVD-Ig) drug conjugate comprising the following structure:
wherein n is 2, and wherein the DVD-Ig binds human STEAP1 and human PSMA, and comprises two identical heavy chains and two identical light chains;
wherein each of the heavy chains comprise the amino acid sequence of SEQ ID NO: 1 or 24; and
wherein each light chain comprises the amino acid sequence of SEQ ID NO: 11.

### Claim 15

A method of making a pharmaceutical composition, comprising mixing:
a. a dual-variable domain immunoglobulin (DVD-Ig) drug conjugate comprising the following structure:
wherein n is 2, and wherein the DVD-Ig binds human STEAP1 and human PSMA, and comprises two identical heavy chains and two identical light chains, wherein each of the heavy chains comprise the amino acid sequence of SEQ ID NO: 1 or 24, and wherein each light chain comprises the amino acid sequence of SEQ ID NO: 11; and
b. a pharmaceutically acceptable carrier.

### Claim 16 (depends on 14)

A method of treating prostate cancer comprising administering a therapeutically effective amount of the pharmaceutical composition according to claim 14 to a subject in need thereof.

### Claim 17

A nucleic acid encoding a heavy chain comprising the amino acid sequence shown as SEQ ID NO: 1 or 24, and/or a light chain comprising the amino acid sequence shown as SEQ ID NO: 11.

### Claim 18

A composition comprising:
a. a reduced DVD-Ig comprising two identical heavy chains comprising the amino acid sequence shown as SEQ ID NO: 1 or 24, and two identical light chains comprising the amino acid sequence shown as SEQ ID NO: 11; and
b. a linker drug of formula (V):

### Claim 19

A process for making a dual-variable domain immunoglobulin (DVD-Ig) drug conjugate of the following structure:
wherein n is 2, and wherein the DVD-Ig binds human STEAP1 and human PSMA and comprises two identical heavy chains and two identical light chains, wherein each of the heavy chains comprise the amino acid sequence of SEQ ID NO: 1 or 24, and wherein each light chain comprises the amino acid sequence of SEQ ID NO: 11, comprising the steps of:
a. reducing with a reducing agent a plurality of DVD-Igs comprising two identical heavy chains comprising the amino acid shown as SEQ ID NO: 1 or 24, and two identical light chains comprising the amino acid sequence shown as SEQ ID NO: 11; and
b. conjugating the plurality of reduced DVD-Ig molecules with an excess of a linker drug of formula (V):
